Dr. Reddy's Laboratories Ltd.
₹1,350.20+₹11.70 (+0.9%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹99,417 Cr
- P/E
- 18.4x
- EV / EBITDA
- 14.3x
- Revenue
- ₹23,115 Cr
- Net margin
- 22.3%
- ROCE
- 23.7%
Price chart
Technical chartScreen technicals →+12.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +9.2%
- 3M
- +18.0%
- 6M
- +2.1%
- 1Y
- +12.3%
- 5Y
- +41.6%
52-week range
Day change +₹11.70 (+0.9%) from ₹1,339 to ₹1,350 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in DRREDDY, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 17.9%
Concerns1
- Negative free cash flow (₹1472 Cr)
Rule-based from financial data. Not advice.
About the company
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Read moreShow less
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 83.5 Cr shares
- ISIN
- INE089A01031
- BSE code
- 500124
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹99,417 Cr
- P/E
- 18.4x
- P/B
- 3.2x
- EV / EBITDA
- 14.3x
- EV / Sales
- 5.0x
- P/S
- 5.1x
- Earnings yield
- 5.4%
- 52-week high
- ₹1,376.30
- 52-week low
- ₹1,135.65
Profitability
- Operating margin
- 30.4%
- Net margin
- 22.3%
- EBITDA margin
- 34.8%
- ROE
- 17.9%
- ROCE
- 23.7%
- ROA
- 14.3%
- Dividend payout
- 15.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 14.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹23,115 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 18.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹6,788 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 41.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 23.2%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.1%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹3,450 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -31.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹118 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.6%
Solvency and efficiency
- Current ratio
- 4.05
- Debt / Equity
- 0.03
- Debt / Assets
- 0.03
- Debt / EBITDA
- 0.12
- Interest coverage
- 269.36
- Financial leverage
- 1.25
- CFO / Net profit
- 0.79
- Cash / Market cap
- 14.3%
- Cash per share
- ₹170.58
- Asset turnover
- 0.64
- Fixed asset turnover
- 2.57
- Capital intensity
- 0.39
- Debtor days
- 87 days
- Inventory turnover
- 1.25
- Cash conversion cycle
- 230 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹23 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹15,690 Cr |
| Sales | Operating profit | ₹7,425 Cr |
| Operating profit | Interest | ₹110 Cr |
| Operating profit | Depreciation | ₹1,039 Cr |
| Operating profit | Profit before tax | ₹6,276 Cr |
| Other income | Profit before tax | ₹961 Cr |
| Profit before tax | Tax and other | ₹1,887 Cr |
| Profit before tax | Net profit | ₹5,349 Cr |
Revenue and net profit
Revenue grew 18.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹13,349 Cr | ₹2,186 Cr |
| FY2022 | ₹14,405 Cr | ₹1,623 Cr |
| FY2023 | ₹16,962 Cr | ₹2,613 Cr |
| FY2024 | ₹19,484 Cr | ₹4,342 Cr |
| FY2025 | ₹23,115 Cr | ₹5,349 Cr |
Cash flows
FY2025: ₹4,225 Cr from operations, -₹1,472 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹3,514 Cr | ₹2,060 Cr |
| FY2022 | ₹1,339 Cr | -₹651 Cr |
| FY2023 | ₹5,053 Cr | ₹1,650 Cr |
| FY2024 | ₹3,450 Cr | ₹21 Cr |
| FY2025 | ₹4,225 Cr | -₹1,472 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹23,115 Cr+18.6%1Y
- Net profit
- ₹5,349 Cr+23.2%1Y
- Cash from operations
- ₹4,225 Cr
- Free cash flow
- -₹1,472 Cr-7,109.5%1Y
- Revenue CAGR, 5Y
- 10.5%
- EBITDA CAGR, 5Y
- 13.4%
- Net profit CAGR, 5Y
- 8.1%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹23,115 Cr | ₹7,425 Cr | — | ₹5,349 Cr | ₹4,225 Cr | -₹1,472 Cr | 18.5% | +18.6% | +23.2% |
Monthly returns
Month-by-month returns of DRREDDY across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹38,291 Cr |
| Equity capital | ₹83 Cr |
| Reserves | ₹28,773 Cr |
| Borrowings | ₹3,493 Cr |
| Other liabilities | ₹5,941 Cr |
| Assets | ₹38,291 Cr |
| Fixed assets | ₹8,232 Cr |
| Capital work in progress | ₹2,197 Cr |
| Investments | ₹13,194 Cr |
| Other assets | ₹14,668 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
DRREDDY trades at 18.4x earnings against a peer median of 52.6x (a 65% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd.DRREDDYthis companyP/E ↓ discount | ₹99,417 Cr | 18.4x | 3.2x | 17.9% | 14.3x |
| Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.3 L Cr | 62.5x | 15.8x | 19.9% | 45.6x |
| Cipla Ltd.CIPLA | ₹1.2 L Cr | 22.5x | 3.5x | 14.6% | 19.3x |
| Apollo Hospitals Enterprises Ltd.APOLLOHOSP | ₹1.1 L Cr | 75.0x | 11.3x | 13.1% | 54.4x |
| Max Healthcare Institute LimitedMAXHEALTH | ₹1.0 L Cr | 144.0x | 11.8x | 8.9% | 96.8x |
| Lupin LtdLUPIN | ₹99,475 Cr | 18.6x | 3.7x | 11.3% | 27.4x |
| Mankind Pharma LimitedMANKIND | ₹91,284 Cr | 54.8x | 5.9x | 19.3% | 34.3x |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹90,637 Cr | 18.8x | 4.2x | 21.9% | 18.4x |
| Alkem Laboratories LimitedALKEM | ₹70,090 Cr | 31.4x | 5.1x | 16.6% | 33.0x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
DRREDDY since 1 January, against earlier years.
Historical volatility
DRREDDY's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 24.0% |
| FY2022 | 18.0% |
| FY2023 | 25.0% |
| FY2024 | 30.0% |
| FY2025 | 32.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹23,115 Cr |
| Costs | |
| Interest | ₹110 Cr |
| Expenses | ₹15,691 Cr |
| Operating profitOperating Profit | ₹7,425 Cr |
| Other income and charges | |
| Profit before tax | ₹7,236 Cr |
| Tax | |
| Net profitNet Profit | ₹5,349 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹38,291 Cr |
| Equity capitalEquity Capital | ₹83 Cr |
| Reserves | ₹28,773 Cr |
| Borrowings | ₹3,493 Cr |
| Other liabilitiesOther Liabilities | ₹5,941 Cr |
| AssetsTotal Assets | ₹38,291 Cr |
| Fixed assetsFixed Assets | ₹8,232 Cr |
| Capital work in progressCWIP | ₹2,197 Cr |
| Investments | ₹13,194 Cr |
| Other assetsOther Assets | ₹14,668 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹4,225 Cr |
| Investing cash flowCash from Investing Activity | -₹5,697 Cr |
| Financing cash flowCash from Financing Activity | ₹1,591 Cr |
| Change in cashNet Cash Flow | ₹118 Cr |
Learn while you research
Academy chapters picked for Dr. Reddy's Laboratories Ltd. and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read